卡地纳健康(CAH)

搜索文档
Best Growth Stocks to Buy for March 8th
Zacks Investment Research· 2024-03-08 16:11
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 8:Powell Industries, Inc. (POWL) : This custom equipment manufacturer has seen the Zacks Consensus Estimate for its current year earnings increasing 44.2% over the last 60 days.Powell Industries has a PEG ratio of 1.53 comparedwith 1.64 for the industry. The company possesses a Growth Score of A.Cardinal Health, Inc. (CAH) : This healthcare services and products company carries a Zacks Rank #1, and ...
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Zacks Investment Research· 2024-03-07 23:40
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...
Best Growth Stocks to Buy for March 6th
Zacks Investment Research· 2024-03-06 18:21
PagSeguro Digital Ltd. - 今年的盈利预期增长了5.1%[1] - PEG比率为1.03,行业平均为1.89[2] Cardinal Health, Inc. - 今年的盈利预期增长了5.7%[3] - PEG比率为1.09,行业平均为3.22[4] NVIDIA Corporation - 今年的盈利预期增长了16.4%[5] - PEG比率为1.24,行业平均为1.56[6]
3 Top-Ranked Stocks to Buy for Stability
Zacks Investment Research· 2024-03-06 06:26
Low-beta stocks can provide several beneficial advantages for portfolios, including defensive qualities and stabilization when combined with high-beta stocks, helping to provide a more balanced risk profile.And for those seeking a less volatile approach, three low-beta stocks – Cigna Group (CI) , Cardinal Health (CAH) , and W.R. Berkley (WRB) – could be considered. All three sport a favorable Zacks Rank, carry solid growth, and sport sound valuations.Below is a chart illustrating the performance of each ove ...
Best Growth Stocks to Buy for March 4th
Zacks Investment Research· 2024-03-04 20:26
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 4:PagSeguro Digital Ltd. (PAGS) : This fintech services company carries seen the Zacks Consensus Estimate for its current year earnings increasing 5.1% over the last 60 days.PagSeguro Digital has a PEG ratio of 1.07 compared with 2.70 for the industry. The company possesses a Growth Scoreof B.Cardinal Health, Inc. (CAH) : This healthcare services and products company carries a Zacks Rank #1, and has ...
Best Momentum Stocks to Buy for March 1st
Zacks Investment Research· 2024-03-02 00:00
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 1:SPX Technologies, Inc. (SPXC) : Thiscompany that supplies infrastructure equipment has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.SPX Technologies' shares gained 29.6% over the last three months compared with the S&P 500’s advance of 9.7%. The company possesses a Momentum Score of A.Cardinal Health, Inc. (CAH) : T ...
Cardinal Health annual research report examines milestone year in biosimilars
Prnewswire· 2024-02-29 19:00
生物类似药物报告 - Cardinal Health发布2024年度生物类似药物报告,分析生物类似药物领域的关键经济、竞争、立法和社会发展[1] - 报告强调了立法发展和新治疗方法,包括阿达木单抗生物类似药物,以及视网膜专家对生物类似药物的看法[1] - 报告还包括对不断发展的支付者格局、管理生物类似药物库存的新实践、生物类似药物如何促进医疗系统可持续性以及生物类似药物产品管道的深入分析[4] 生物类似药物节省作用 - 生物类似药物的节省将在资助创新新治疗方法和减轻医疗系统整体财务负担之间发挥越来越重要的作用[2] 视网膜专家对生物类似药物的看法 - Cardinal Health调查眼科提供者,发现80%的参与者对生物类似药物非常熟悉,但不到60%曾为视网膜疾病治疗开具生物类似药物处方[3] - 82%的视网膜专家表示,如果生物类似药物成为支付者首选药物,他们将更有可能开具生物类似药物处方[3] - 研究还表明,75%的参与者认为生物类似药物对医疗系统的可持续性有潜在影响[3]
Bob Azelby to join Cardinal Health Board of Directors
Prnewswire· 2024-02-29 05:15
DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, an ...
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
Zacks Investment Research· 2024-02-29 02:46
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...
How to Find Top-Ranked Stocks to Buy in March
Zacks Investment Research· 2024-02-28 04:31
The S&P 500 is trading near fresh all-time highs as the market prepares to turn the page on February. The market made it through Q4 earnings season as confident as ever in the possibility of a soft landing for the U.S. economy. The market has taken a much-deserved respite to start the final week of February. Wall Street is now likely waiting on the Fed’s preferred inflation data out later this week before it makes its next decisive move in either direction. No matter how the PCE data looks, it is worth s ...